InvestorsHub Logo
Followers 48
Posts 6547
Boards Moderated 1
Alias Born 01/19/2006

Re: None

Monday, 08/28/2017 11:31:36 AM

Monday, August 28, 2017 11:31:36 AM

Post# of 236
Aequus and Ehave Collaborate on Bioinformatics Platform for Management of Clinical Trials

VANCOUVER, BC--(Marketwired - August 28, 2017) - Aequus Pharmaceuticals Inc. (TSX VENTURE: AQS) (OTCQB: AQSZF) ("Aequus" or the "Company"), a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, and Ehave, Inc. (OTCQB: EHVVF) ("Ehave"), a healthcare bioinformatics company whose platform efficiently captures, integrates, and delivers high-quality clinical data and treatment tools, have entered into a collaboration whereby Aequus will gain access to Ehave's bioinformatics platform for use in Aequus' anticipated clinical trials for its portfolio products, with an initial focus in neurology. The two companies plan to collaborate on conducting trials in both the traditional pharmaceutical drug regulatory regime and in the medical cannabis regulatory regime. Aequus will pay Ehave a per-patient fee for trials conducted using the Ehave bioinformatics platform and will receive patient assessment, diagnostic and therapeutic outcomes and side-effect profiles content from formal and informal studies conducted using the Ehave platform, subject to standard patient consent and clinical research ethics approvals. Aequus will own all clinical results and data generated from trials using the Ehave platform.

"We are excited to work with Ehave as we advance various development programs, both our traditional pharmaceutical products and medical cannabinoid containing products, through clinical trials," says Doug Janzen, Chairman and CEO of Aequus. "This partnership will allow Aequus to capture patient outcomes of product safety and efficacy in a variety of trial settings in a very efficient and cost-effective way. We believe the Ehave platform is ideally suited for monitoring and assessing product performance in the rapidly evolving medical cannabis space, tracking both patient safety and product efficacy and providing clinicians and drug developers like Aequus and our partners with robust clinical data in a real-world setting, something that is currently lacking and that the medical community has been asking for."

"Our core technology platform allows us to provide customized, next-generation clinical solutions that empower pharmaceutical developers to be successful by streamlining patient management and data collection, reducing errors and data loss, improving patient compliance, and ultimately saving valuable time and costs," said Prateek Dwivedi, CEO of Ehave. "We're pleased to partner with Aequus and to support the clinical evaluation of its pharmaceutical and cannabinoid drug candidates. We believe this partnership will demonstrate how the Ehave platform may mitigate certain data management challenges facing researchers in neurology, and how Ehave can help validate and unlock value for new pharmaceutical and medical cannabis products."